Priority Lists
Protocol Posting of
Activations
Closures
Permanent Closure effective 1/10/07.
Phase III Randomized, Placebo-Controlled, Trial of Docetaxel Versus Docetaxel Plus ZD1839 (Iressa, Gefitinib) in Performance Status 2 or Previously Treated Patients with Recurrent or Metastatic Head and Neck Cancer
| Study Coordinator(s) | Stephen K. Williamson, M.D. |
| Participants | CTSU |
| Closure Date | 2007-01-10 |
Permanent Closure to SWOG institutions effective 1/10/07
Phase III Randomized Study of Four Weeks of High Dose IFN-alpha2b in Stage T2b N0, T3a-b N0, T4a-b N0, and T1-4, N1a, 2a, 3(Microscopic) Melanoma
| Study Coordinator(s) | Lawrence E. Flaherty, M.D. |
| Participants | CTSU |
| Closure Date | 2010-10-27 |
Permanent Closure
A Randomized Clinical Trial of Adjuvant Chemotherapy for Radically Resected Loco-Regional Relapse of Breast Cancer
| Study Coordinator(s) | Anne F. Schott, M.D. |
| Participants | CTSU |
| Closure Date | 2007-01-10 |
Permanent Closure effective 1/10/07.
Adjuvant Chemo-Radiotherapy with Combination of Cisplatin (NSC-119875)and Docetaxel (NSC-628503) After Complete Resection of Locally Advanced (Stage III and IV) Squamous Cell Carcinoma of the Head and Neck (SCCHN)
| Study Coordinator(s) | Prakash C. Neupane, M.D., Harold Kim, M.D., Stephen K. Williamson, M.D., George Yoo, M.D. |
| Participants | Members, NCORP, Affiliates, Medical Oncologists, Radiation Oncologists, Surgeons, Pathologists |
| Closure Date | 2007-01-10 |
Permanent Closure
Phase II Study of Irinotecan in Patients with Advanced Transitional Cell Carcinoma of the Urothelium
| Study Coordinator(s) | Tomasz M. Beer, M.D., Craig R. Nichols, M.D. |
| Participants | Members, NCORP, Affiliates, UCOP, Medical Oncologists, Surgeons |
| Closure Date | 2007-02-01 |
Partial Permanent Closure
A Phase IIb Study of Molecular Responses to Imatinib, at Standard or Increased Doses, or Dasatinib (BMS-354825) (NSC-732517) for Previously Untreated Patients With Chronic Myelogenous Leukemia (CML) in Chronic Phase.
| Action Codes | ER |
| Study Coordinator(s) | Brian J. Druker, M.D., Marilyn L. Slovak, Ph.D., Jerald P. Radich, M.D. |
| Participants | Members, NCORP, Medical Oncologists, Pathologists, ECOG, CALGB, NCIC-CTG |
| Closure Date | 2009-02-28 |
Permanent Closure effective 1/10/07
A Phase III Trial of Standard Fractionation Radiation and Concurrent Single Agent Cisplatin, with and without Docetaxel, Cisplatin, and 5-Fluorouracil Induction Chemotherapy, in Patients with Advanced Oropharyngeal Squamous Cell Cancer
| Action Codes | ER |
| Study Coordinator(s) | David J. Adelstein, M.D., Gregory T. Wolf, M.D., P.G. Shankar Giri, M.D., Adel K. El-Naggar, M.D., Ph.D, Peggy A. Carroll, R.N. |
| Participants | Members, NCORP, Affiliates, Medical Oncologists, Radiation Oncologists, Surgeons, Pathologists, CTSU |
| Closure Date | 2007-01-10 |
Permanent Closure effective 1/10/07
Phase II Study of Trastuzumab (NSC-688097) in Advanced High Grade Salivary Gland Carcinoma
| Study Coordinator(s) | Madeleine Kane, M.D., Ph.D, Adel K. El-Naggar, M.D., Ph.D, Stephen K. Williamson, M.D. |
| Participants | Members, NCORP, Medical Oncologists, ECOG |
| Closure Date | 2007-01-10 |
Permanent Closure
Nonmyeloablative Allogeneic Stem Cell Transplantation for Relapsed Hodgkin's or Non-Hodgkin's Lymphoma After Autologous Transplantation (A BMT Study)
| Study Coordinator(s) | Scott E. Smith, M.D., Ph.D, Patrick J. Stiff, M.D. |
| Participants | Limited Institutions: Allogeneic BMT Members |
| Closure Date | 2007-01-10 |
Permanent Closure effective 1/10/07
Phase II Trial of PS-341 (Bortezomib, NSC-681239) Followed by the Addition of Gemcitabine at Progression in Recurrent or Metastatic Nasopharyngeal Carcinoma
| Study Coordinator(s) | Sai-Hong Ignatius Ou, M.D., Ph.D, Stephen Shibata, M.D. |
| Participants | Members, NCORP, Affiliates, Medical Oncologists |
| Closure Date | 2007-01-10 |
Permanent Closure
A Phase II Study of Goserelin Plus Anastrozole for the Treatment of Male Patients With Hormone-Receptor Positive Metastatic or Recurrent Breast Cancer"
| Study Coordinator(s) | Zeina Nahleh, M.D., Abdul-Rahman Jazieh, M.D., Robert B. Livingston, M.D. |
| Participants | Members, NCORP, Medical Oncologists |
| Closure Date | 2007-01-10 |
Amendments, Revisions, Memoranda
Memorandum
Phase III Chemoprevention Trial of Selenium Supplementation in Persons with Resected Stage I Non-Small Cell Lung Cancer
| Study Coordinator(s) | Omer Kucuk, M.D. |
| Participants | Members, NCORP, Medical Oncologists, Surgeons |
Memorandum
A Phase II Study of Pemetrexed Disodium (ALIMTA) Plus Bevacizumab in Patients with Stage IIIB Pleural Effusion or Stage IV Non-Small Cell Lung Cancer (Second-Line Treatment)
| Study Coordinator(s) | Ralph G Zinner, M.D. |
| Participants | Members, NCORP, Affiliates, Medical Oncologists |
Memorandum
Randomized Phase III Trial of Cisplatin and Irinotecan versus Cisplatin and Etoposide in Patients with Extensive Stage Small Cell Lung Cancer
| Study Coordinator(s) | Ronald B. Natale, M.D., David R. Gandara, M.D., Primo N. Lara, Jr., M.D., Heinz- Josef Lenz, M.D. |
| Participants | Members, NCORP, Affiliates, Medical Oncologists, Pathologists, CTSU |
Revision #3
Randomized Placebo-Controlled Biomarker Modulation Trial Using Celecoxib in Premenopausal Women at High Risk for Breast Cancer
| Study Coordinator(s) | Powel H. Brown, M.D., Ph.D, G. Thomas Budd, M.D. |
| Participants | Members, NCORP, Affiliates, Medical Oncologists |
Memorandum
Phase III Trial of Bisphosphonates as Adjuvant Therapy for Primary Breast Cancer
| Study Coordinator(s) | Julie R. Gralow, M.D., Robert B. Livingston, M.D., Daniel F. Hayes, M.D., Dawn Hershman, M.D., M.S., Alison T. Stopeck, M.D. |
| Participants | Members, NCORP, Affiliates, Medical Oncologists, Surgeons, Pathologists, CTSU |
Revision #3
A Phase II Study of the RAF-Kinase Inhibitor BAY 43-9006 (NSC-724772, IND-69,896) in Combination with Interferon Alpha 2b in Patients wtih Advanced Renal Cancer
| Study Coordinator(s) | Christopher W. Ryan, M.D., Tomasz M. Beer, M.D., Paul H. Gumerlock, Ph.D. |
| Participants | Members, NCORP, UCOP, Medical Oncologists, Surgeons, Pathologists |
Revision #3
Molecular Epidemiology Case-Series Study of Non-Small Cell Lung Cancer in Smoking and Non-Smoking Women and Men
| Action Codes | ER |
| Study Coordinator(s) | Christine B. Ambrosone, Ph.D., Regina M. Santella, Ph.D., Mary Reid, Ph.D., Philip C. Mack, Ph.D. |
| Participants | Members, NCORP, Medical Oncologists, Pathologists, CTSU, CALGB, ECOG, NCCTG, RTOG |
Revision #1
A Phase II Trial of Cytarabine and Clofarabine in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)
| Action Codes | IP, AC, ER |
| Study Coordinator(s) | Anjali S. Advani, M.D., Jerald P. Radich, M.D., Marilyn L. Slovak, Ph.D. |
| Participants | Members, NCORP, Affiliates, Medical Oncologists |
Memorandum
Chemoprevention of Prostate Cancer with Finasteride (Proscar®), Phase III, Intergroup
| Study Coordinator(s) | Ian M. Thompson Jr., M.D., Michael K. Brawer, M.D., E. David Crawford, M.D. |
Other New Items
- IP - Pts Must Be Informed
- AC - Consent Must Be Amended
- CBR - No Registration Allowed until IRB Review
- RC - Formal Re-consent Required
- FBR - Full Board Review Required
- ER - Expedited Review Acceptable
- NR - No IRB Review Required